BioSpace News Archive

PTC Therapeutics, Inc. announced that the company will present a company overview at the following conference.

VolitionRx Limited, a multi-national epigenetics company, announced that Cameron Reynolds, President and Group Chief Executive Officer, will present and be available for one-to-one meetings at the Jefferies Global Healthcare Conference in New York City.

BioLife Solutions, Inc., a leading supplier of bioproduction tools and services for the cell and gene therapy and broader biopharma markets, announced the introduction of the CryoCase, an addition to its CellSeal product line.

NewBiologix SA, a technology innovation company focused on addressing gene and cell therapy manufacturing gaps, announced the launch of NBX-HEK293, the Company’s engineered host HEK293 cell line for the production of recombinant adeno-associated viruses used in gene therapy.

Montai Therapeutics is expanding its network of renowned scientific and technical advisors with the appointment of Larry Hamann to its Board of Directors and the launch of the company’s Scientific Advisory Board (SAB).

Equillium, Inc. today announced that it will present at the Jefferies Global Healthcare Conference taking place at the Marriott Marquis in New York, NY, June 4 – 6, 2024.

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced that Company management will participate in the Jefferies Global Healthcare Conference, taking place June 5-6, 2024, in New York.

Stereotaxis, a pioneer in surgical robotics for minimally invasive endovascular intervention, announces the successful treatment of the first heart rhythm patients by Penn Presbyterian Medical Center utilizing the advanced Genesis Robotic Magnetic Navigation System.

Georgiamune Inc., a privately held, clinical-stage biotechnology company, announced the clearance of its second Investigational New Drug application by the U.S. Food and Drug Administration for GIM-531, a first-in-class oral treatment that selectively targets T-regulatory cells and spares other immune cells such as CD4 and CD8.

Median Technologies announced that the Company will be participating in the 2024 American Society of Clinical Oncology Annual Meeting taking place from May 31 to June 4, McCormick Place, Chicago, IL, USA.